Full text is available at the source.
Abstract
Over 12,300 patients were included in the analysis of tirzepatide's efficacy for weight loss.
- Weekly tirzepatide 10 and 15 mg resulted in greater weight loss compared to weekly semaglutide 2.4 mg, daily semaglutide 0.4 mg, or liraglutide 3 mg.
- Tirzepatide and weekly semaglutide showed similar efficacy, but tirzepatide had significantly higher odds of achieving ≥5%-20% weight loss compared to liraglutide.
- More gastrointestinal adverse events were reported with GLP-1 receptor agonists compared to placebo, with no significant difference between the drugs.
- All GLP-1 receptor agonists evaluated resulted in significant weight reduction, with tirzepatide showing better efficacy outcomes.
Simplified